Actelion Acquires Option to Buy CNS Drug Developer Trophos
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 8 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1363 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Actelion, the Swiss maker of the blockbuster pulmonary arterial hypertension drug Tracleer® (bosentan), has entered into an option agreement to acquire Trophos, based on the success of its Phase III candidate to treat amyotrophic lateral sclerosis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS